Reversal of β cell de-differentiation by a small molecule inhibitor of the TGFβ pathway

Area of Science:

• Endocrinology
• Cell Biology
• Diabetes Research

Background:

• Pancreatic beta cell (β cell) dysfunction or death is central to both type 1 and type 2 diabetes.
• β cell functional decline is preceded by cellular stress and dedifferentiation.
• Existing type 2 diabetes (T2D) therapies manage blood glucose but do not address underlying β cell stress or dedifferentiation.

Purpose of the Study:

• To identify factors capable of reversing β cell dedifferentiation.
• To investigate the role of Urocortin 3 (Ucn3) as a marker for mature β cells in T2D.
• To evaluate the therapeutic potential of targeting TGFβ signaling in diabetes.

Main Methods:

• Utilized an insulin expression-coupled lineage tracer with Ucn3 as a reporter for β cell maturation.
• Screened for compounds that could reverse β cell dedifferentiation.
• Exposed β cells to stress and prolonged/severe diabetes models in vitro and in vivo.

Main Results:

• Urocortin 3 (Ucn3) expression decreases in early T2D stages and under β cell stress.
• A small molecule inhibitor of TGFβ receptor I (Alk5) was identified as a key factor.
• Alk5 inhibition protected β cells from losing critical transcription factors and restored mature β cell identity.

Conclusions:

• Urocortin 3 serves as a reliable marker for mature pancreatic β cells.
• Inhibition of TGFβ receptor I (Alk5) effectively reverses β cell dedifferentiation.
• Targeting TGFβ signaling presents a promising therapeutic strategy for type 2 diabetes by restoring β cell function.